Newron Pharmaceuticals SpA Osinko 2024

Mitä Newron Pharmaceuticals SpA tekee?

Newron Pharmaceuticals SpA is an international biopharmaceutical company specializing in the development of novel products for the treatment of central nervous system (CNS) disorders. The company is headquartered in Italy and is listed on the SIX Swiss Exchange. The history of Newron Pharmaceuticals SpA dates back to 1996 when it was founded by a team of experienced pharmaceutical experts. Since then, the company has become a leading player in the development of therapies for rare neurological disorders. The focus is particularly on diseases such as Parkinson's and Rett syndrome, as well as other neurological disorders. Newron Pharmaceuticals SpA's business model is based on the research and development of novel drugs in the field of the central nervous system. The company typically conducts research and development in its own laboratories and collaborates closely with external experts and institutions to develop innovative therapies. The goal is to develop patient-oriented, innovative drugs and successfully bring them to market. The company has several product candidates in various stages of development, including Xadago® (Safinamide), an approved drug for the treatment of Parkinson's. Similarly, an orally administered drug is being tested in phase III of clinical development with the aim of improving motor symptoms in Parkinson's. Another important product candidate of Newron Pharmaceuticals SpA is Sarizotan, an innovative drug for the treatment of Rett syndrome, a rare neurological disease that primarily affects girls. The company has entered into a partnership with the American company Rett Syndrome Research Trust (RSRT) to promote further development of the drug. In addition to researching and developing new drugs, Newron also actively works on advancing existing treatment approaches. For example, collaborations with academic institutions are used to incorporate new knowledge from the fields of molecular biology and genetics to further expand existing therapeutic approaches. The company follows an integrative approach, focusing on collaboration between research and development teams, clinical experts, patient organizations, and regulatory authorities. The goal is to treat patients with novel and effective therapies. Overall, Newron Pharmaceuticals SpA is an internationally operating biopharmaceutical company dedicated to researching and developing novel therapies in the field of the central nervous system. Through its innovative research and development activities and close collaboration with experts, institutions, and patient organizations, the company significantly contributes to the advancement of treatment options for neurological disorders. Newron Pharmaceuticals SpA on yksi suosituimmista yrityksistä Eulerpool.com-sivustolla.